|
Match
|
Document |
Document Title |
|
|
US20090304801 |
AEROSOL AND INJECTABLE FORMULATIONS OF NANOPARTICULATE BENZODIAZEPINE
Described are nanoparticulate formulations of a benzodiazepine, such as lorazepam, that does not require the presence of polyethylene glycol and propylene glycol as stabilizers, and methods of...
|
|
|
US20090306049 |
Treatment of Barrett's Esophagus
The invention relates to the field of biochemistry and medicine. More specifically, the invention relates to the treatment of epithelial changes in the esophagus. Even more specific, the invention...
|
|
|
US20090306051 |
Methods and compositions for the treatment of epilepsy, seizure disorders, and other CNS disorders
The present invention relates to methods and compositions for treating CNS-related disorders.
|
|
|
US20090297619 |
NANOPARTICULATE ANTICONVULSANT AND IMMUNOSUPPRESSIVE COMPOSITIONS
Described are controlled release nanoparticulate formulations comprising a nanoparticulate agent to be administered and a rate-controlling polymer which functions to prolong the release of the...
|
|
|
US20090298785 |
Method for Treating Ocular Cancer
It has now been found that the p53 pathway is inactivated in ocular cancers such as retinoblastoma. As such, the present invention is a method for inducing ocular cancer cell death using a p53...
|
|
|
US20090291938 |
POLO-LIKE KINASE INHIBITORS
Compounds of the following formula are provided for use with kinases:
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture...
|
|
|
US20090281082 |
COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS
The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of...
|
|
|
US20090281092 |
POLO-LIKE KINASE INHIBITORS
Compounds of the following formula are provided for use with kinases:
wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture...
|
|
|
US20090270367 |
SUBSTITUTED HYDROXYETHYLAMINE ASPARTYL PROTEASE INHIBITORS
The invention relates to novel compounds and also to methods of treating at least one disease, disorder, or condition associated with amyloidosis using such compounds. Amyloidosis refers to a...
|
|
|
US20090270341 |
PRODUCT COMPRISING A TRANSDUCTION INHIBITOR OF HETEROTRIMERIC G PROTEIN SIGNALS COMBINED WITH ANOTHER ANTI-CANCER AGENT FOR THERAPEUTIC USE IN THE TREATMENT OF CANCER
A composition for treating cancer comprising an anti-tumorally effective amount of a product comprising at least one transduction inhibitor of heterotrimeric G protein signals and at least one...
|
|
|
US20090264419 |
CYCLIC MALONAMIDES AS INHIBITORS OF Abeta PROTEIN PRODUCTION
This invention relates to novel cyclic malonamides having the formula (I):
to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of...
|
|
|
US20090264420 |
ORGANIC COMPOUNDS
The present invention provides a compound of formula I:
said compound is inhibitor of aldosterone synthase, and/or 11 beta-hydroxylase (CYPL11B1), and/or aromatase, and thus can be employed for...
|
|
|
US20090258865 |
ADMINISTRATION OF BENZODIAZEPINE COMPOSITIONS
The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.
|
|
|
US20090258864 |
PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES
This invention is directed to compounds of formula (I):
where
n, m, Y, R 1 , R 2 , R 3 , R 4 and R 5 are disclosed herein, as isolated stereoisomers or mixtures thereof, or as...
|
|
|
US20090258866 |
CGRP Receptor Antagonists
The disclosure generally relates to the novel compounds of formula I, including their salts, which are CGRP receptor antagonists. The disclosure also relates to pharmaceutical compositions and...
|
|
|
US20090258856 |
IMIDAZOPYRIDAZINONE AND IMIDAZOPYRIDONE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS
The present invention relates to substituted imidazo-pyridinones and imidazo-pyridazinones of general formula
wherein Y and R 1 to R 4 are defined as in claim 1 , the tautomers, enantiomers,...
|
|
|
US20090253685 |
Product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent
A subject of the invention is a product comprising at least one Cdc25 phosphatase inhibitor in combination with at least one other anti-cancer agent for a therapeutic use which is simultaneous,...
|
|
|
US20090253686 |
UNSOLVATED BENZODIAZEPINE COMPOSITIONS AND METHODS
The present invention relates to systems and methods for generating new forms of benzodiazepine and benzodiazepine related compounds as well as new compounds and formulations generated by such...
|
|
|
US20090239841 |
Diaryl Ureas as CB1 Antagonists
Compounds of Formula I are provided. In which the variables are as described herein. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the...
|
|
|
US20090233912 |
NON-AQUEOUS PHARMACEUTICAL COMPOSITION
A composition for intranasal delivery of a drug comprising: includes: (i) the drug; and (ii) a non-aqueous vehicle containing (a) propylene glycol and at least one additional solvent selected from...
|
|
|
US20090233913 |
OPTICAL ISOMERS OF DIHYDRO-2,3-BENZODIAZEPINES AND THEIR STEREOSELECTIVE SYNTHESIS
The present invention relates to dihydro-2,3-benzodiazepine compounds of high enantiomeric purity according to the general formula (I), which contain an asymmetric centre at the position 4 of the...
|
|
|
US20090227595 |
GLYCINE TRANSPORTER-1 INHIBITORS
The present invention provides compounds that are glycine transporter 1 (hereinafter referred to as GlyT-1) inhibitors and are therefore useful for the treatment of diseases treatable by inhibition...
|
|
|
US20090226522 |
PROCESS TO MINIMIZE POLYMORPHISM
The commercial formulation of fast dispersing dosage forms (FDDF) requires substantial holding times during which large quantities of pharmaceutically active substance are formed into individual...
|
|
|
US20090221549 |
ANTIHYPERTENSIVE THERAPY
A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or...
|
|
|
US20090221562 |
NOVEL OPIOID ANTAGONISTS
Certain quinolizidine and octahydropyridopyrazine compounds, pharmaceutical compositions, and methods of their use, inter alia, as opioid receptor antagonists are disclosed.
|
|
|
US20090221561 |
Cell Migration Modulating Compounds
The described invention relates to compounds which modulate cell migration, and find use in, for example, wound healing, cancer progression and angiogenesis.
|
|
|
US20090215752 |
Compounds, preparation and therapeutic use thereof
The invention relates to benzodiazepine derivatives having PDE2 inhibitory activities, as well as therapeutic methods of administering said compounds, in particular for treating various diseases of...
|
|
|
US20090215753 |
Topical Compositions for Paediatric Use
The present invention provides pharmaceutical compositions for treating a paediatric mammal, the compositions comprising a therapeutic agent and a pharmaceutically acceptable carrier, the...
|
|
|
US20090209473 |
Componds and methods for pormoting angiogenesis
Angiogenesis may be initiated or increased through the use of gamma-secretase inhibitors. The gamma-secretase inhibitor can be a dipeptide class, sulfonamide class, transition state mimic class,...
|
|
|
US20090203669 |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ADDICTION AND OTHER NEUROPSYCHIATRIC DISORDERS
The present invention is based, in part, on our discovery that certain types of therapeutic agents can be used in combination to treat a variety of neuropsychiatric and related disorders, including...
|
|
|
US20090203670 |
Combination Antidepressants Wafer
A sheet-like pharmaceutical preparation (dosage form) that quickly disintegrates on contact with moisture, based on hydrophilic polymers for the release of at least one active agent. The dosage...
|
|
|
US20090197873 |
COMPOSITIONS COMPRISING ALPRAZOLAM FOR TREATING PRIMARY INSOMNIA AND INSOMNIA ASSOCIATE WITH ANXIETY STATES AND PROCESS FOR PREPARING THEM
Disclosed is a composition comprising alprazolam for treating primary insomnia and insomnia associated with anxiety states and the corresponding use and method comprising the administration of...
|
|
|
US20090197872 |
NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONYL PYRIMIDINYL DERIVATIVES AND THEIR MEDICAL USE
This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonyl pyrimidinyl derivatives and their use in the manufacture of pharmaceutical compositions. The compounds of the invention are found to be...
|
|
|
US20090192143 |
Substituted diazepan orexin receptor antagonists
The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric...
|
|
|
US20090186880 |
NOVEL 1,4-DIAZA-BICYCLO[3.2.2]NONANE DERIVATIVES AND THEIR MEDICAL USE
This invention relates to novel 1,4-diaza-bicyclo[3.2.2]nonane derivatives, which are found to be cholinergic ligands at the nicotinic acetylcholine receptors and modulators of the monoamine...
|
|
|
US20090181954 |
Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs
The present invention is drawn to transdermal drug formulations, transdermal patches incorporating such formulations, as well as associated methods. The formulations can include about 0.3 wt % to...
|
|
|
US20090169620 |
ORALLY DISINTEGRATING TABLET COMPOSITIONS OF TEMAZEPAM
The compositions of the present invention are orally disintegrating tablet compositions comprising a therapeutically effective amount of at least one drug such as temazepam, 0.5-3% of an ODT binder...
|
|
|
US20090170831 |
SUBSTITUTED LACTAMS AS INHIBITORS OF ABETA PROTEIN PRODUCTION
Field of the Invention This invention relates to novel lactams of Formula (I):
having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel...
|
|
|
US20090162420 |
Matrix-Controlled Transdermal System Comprising Salts of ACE Inhibitor Dicarboxylic Acids
The invention relates to a salt of an ACE inhibitor dicarboxylic acid with an organic amine and/or an alkali compound, a transdermal therapeutic system comprising the salt, and a method of...
|
|
|
US20090163478 |
Salts and Crystal Modifications Thereof
The invention relates to salts of 1-(2-Fluoro-phenyl)-3-(2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e
][1,4]diazepin-3-yl)-urea and crystalline forms thereof, their production and usage, and...
|
|
|
US20090163451 |
METHODS FOR TREATING VISCERAL PAIN
The invention features methods of treating visceral pain in humans by administering an effective amount of a 5HT 1B or 5HT 1D receptor agonist, (e.g., a triptan). These methods can be used, for...
|
|
|
US20090162300 |
BUCCAL, POLAR AND NON-POLAR SPRAY CONTAINING ALPRAZOLAM
Buccal aerosol sprays or capsules using polar and non-polar solvents have now been developed which provide alprazolam for rapid absorption through the oral mucosa, resulting in fast onset of...
|
|
|
US20090156579 |
Combination of a Dipeptidyl Peptidase-4 Inhibitor and an Anti-Hypertensive Agent for the Treatment of Diabetes and Hypertension
The present invention relates to pharmaceutical compositions comprising a combination of a particular dipeptidyl peptidase-4 (DPP-4) inhibitor and an anti-hypertensive agent selected from the group...
|
|
|
US20090156565 |
COMPOSITION AND USE THEREOF IN ENHANCING A THERAPEUTIC EFFECT OF AN ANTIEPILEPTIC DRUG
A composition and a method for the use of the composition for enhancing a therapeutic effect of an antiepileptic drug in treating a seizure in a status epilepticus in an animal. A composition...
|
|
|
US20090156982 |
Transdermal treatment device and method
A treatment device for treating a medical condition comprises a composition selected for its ability to treat the medical condition, the composition being formulated for transdermal delivery. A...
|
|
|
US20090156578 |
3-Heterocyclylacrylamide Compounds as Fab I Inhibitors and Antibacterial Agents
In part, the present invention is directed towards compounds with FabI inhibiting properties. Such compounds may also inhibit other enzymes, including those similar to FabI either structurally or...
|
|
|
US20090156562 |
NOVEL COLORED SOLUTIONS OF INJECTABLE DRUGS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
The invention is directed to pharmaceutical compositions comprising colored solutions, colored emulsions, or colored powders of injectable pharmaceuticals wherein said pharmaceuticals are selected...
|
|
|
US20090149799 |
Method for chemical modulation of neural activity
Methods and related systems for modulating neural activity by repetitively blocking conduction in peripheral neural structures with chemical blocking agents are disclosed. Methods and systems for...
|
|
|
US20090149450 |
SUBSTITUTED IMIDAZOHETEROCYCLES
The present invention provides substituted imidazoheterocyclic compounds having the structure of formula I
Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and...
|
|
|
US20090143361 |
Pyrido[3,2-E]Pyrazines, Process For Preparing The Same, And Their Use As Inhibitors Of Phosphodiesterase 10
The invention relates to pyrido[3,2-e]pyrazines, to processes for preparing them, to pharmaceutical compositions which comprise these compounds and to the pharmaceutical use of these compounds,...
|